Techniclone, Biotechnology Development Ltd., Schering deal

TCLN exercised its option to reacquire from Biotechnology Development European and other marketing rights to its Oncolym radiolabeled monoclonal antibody for a combination of TCLN stock, warrants and a promissory note due in two years. Biotechnology Development will not receive royalties. ...